OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer
Metrics: PDF 1344 views | HTML 2393 views | ?
Hui-Wen Chiu1,2, Hui-Yu Lin1,3, Ing-Jy Tseng4, Michael Hsiao5,6 and Yuan-Feng Lin1
1Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
2Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taiwan
3Department of Breast Surgery and General Surgery, Division of Surgery, Cardinal Tien hospital, Xindian District, New Taipei City, Taiwan
4Gerontology Health Management, College of Nursing, Taipei Medical University, Taipei, Taiwan
5Genomics Research Center, Academia Sinica, Taipei, Taiwan
6Department of Biochemistry, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Yuan-Feng Lin, email: email@example.com
Keywords: OTUD7B; paclitaxel; chemotherapy; in silico analysis; triple-negative breast cancer
Received: August 20, 2017 Accepted: November 14, 2017 Published: December 09, 2017
Paclitaxel is a first-line chemotherapeutic for patients with breast cancer, particularly triple-negative breast cancer (TNBC). Molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed since paclitaxel resistance is still a clinical issue in treating TNBCs. We investigated the transcriptional profiling of consensus genes in HCC38 (paclitaxel-sensitive) and MDA-MB436 (paclitaxel-resistant) TNBC cells post-treatment with paclitaxel. We found that OTUD7B was downregulated in HCC38 but upregulated in MDA-MB436 cells after paclitaxel treatment at cytotoxic concentrations. Moreover, our data showed that OTUD7B expression causally correlated with IC50 of paclitaxel in a panel of TNBC cell lines. Moreover, we found that OTUD7B upregulation was significantly detected in primary breast cancer tissues compared to normal breast tissues but inversely correlated with tumor growth in TNBC cells. Besides, the increased levels of OTUD7B transcript appeared to causally associate with invasive and metastatic potentials in TNBC cells. In assessments of recurrence/metastasis-free survival probability, high-levels of OTUD7B transcripts strongly predicted a poor prognosis and unfavorable response to paclitaxel-based chemotherapy in patients with TNBCs. In silico analysis suggested that OTUD7B regulation, probably owing to miR-1180 downregulation, may negatively regulate the NF-κB-Lin28 axis which in turn triggers Let-7 microRNA-mediated caspase-3 downregulation, thereby conferring paclitaxel resistance in TNBCs. These findings suggest that OTUD7B may be a useful biomarker for predicting the anti-cancer effectiveness of paclitaxel and could serve as a new drug target for enhancing the canceridal efficiency of paclitaxel against TNBCs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.